AJP - Regu AJP: Endocrinology and Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol (June 20, 2007). doi:10.1152/ajpregu.00323.2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/3/R983    most recent
00323.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scott, K. A
Right arrow Articles by Moran, T. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scott, K. A
Right arrow Articles by Moran, T. H.
Submitted on May 8, 2007
Accepted on June 15, 2007

The GLP-1 agonist exendin-4 reduces food intake in non-human primates through changes in meal size

Karen A Scott1 and Timothy H. Moran2*

1 Psychiatry, University of Cincinnati, Cincinnati, Ohio, United States
2 Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States; Department of Psychiatry, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore,, Maryland, 21205, United States

* To whom correspondence should be addressed. E-mail: tmoran{at}jhmi.edu.

Exendin-4 (Ex4), a long acting GLP-1 receptor agonist, has been shown to reduce food intake and suppress gastric emptying in rodents and humans. In this study we investigated the effects of peripheral administration of Ex4 on food intake and meal patterns in adult male rhesus macaques. Rhesus macaques (n=4) that had been trained to lever-press for food pellets were injected intramuscularly (IM) 15 minutes prior to the start of their 6 hr daily feeding period. Ex4 was given at doses of 0.10, 0.32, 0.56, 1.0 and 3.0 µg/kg. Ex4 suppressed food intake in a dose-dependent manner, with the 3.0 µg/kg dose completely preventing feeding during the 6 hr period, and the dose of 0.10 µg/kg suppressing intake by 17%. Doses of 0.32, 0.56, 1.0 and 3.0 µg/kg caused significant reductions in cumulative intake at all 6 hourly time points. Ex4 inhibited food intake through a specific effect on meal size. Meal size was significantly reduced in a dose-dependent manner with significant reductions at the 0.32 and 1.0 µg/kg doses (p<0.05). Day 2 and 3 intakes returned to baseline levels with no compensation for Ex4-induced feeding suppression. Administration of doses of 0.32 and 0.56 µg/kg Ex4 over 5 consecutive days led to sustained reductions in intake with no evidence of compensation. Again, these reductions were due to specific effects on in meal size. These results demonstrate that activation of GLP-1 pathways has potent effects on the controls of meal size and overall food intake in a non-human primate model.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.